Spots Global Cancer Trial Database for Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer
Official Title: Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Non Small Cell Lung Cancer: A Registry-based Phase II Randomized Trial
Study ID: NCT04405401
Conditions
Study Description
Brief Summary: A registry-based randomized screening phase II trial. A total of 68 patients with metastatic non small cell lung cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiotherapy to all oligoprogressive lesions while continuing their current systemic therapy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada
Contact Details
Name: Houda Bahig, MD PhD
Affiliation: Centre hospitalier de l'Université de Montréal (CHUM)
Role: STUDY_CHAIR
Name: Bertrand Routy, MD PhD
Affiliation: Centre hospitalier de l'Université de Montréal (CHUM)
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
